Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00486057 · ClinicalTrials.gov registry record
Daclizumab Experience in Pediatric Heart Transplant
A clinical trial, sponsored by Children's Healthcare of Atlanta.
- Terminated
- Registry status
- 30
- Enrollment target
NCT00486057: Clinical Trial study, sponsored by Children's Healthcare of Atlanta.
NCT00486057 is a clinical trial that was terminated before completion, run by Children's Healthcare of Atlanta. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00486057 was terminated before completion, sponsored by Children's Healthcare of Atlanta.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the outcomes of those who have received Daclizumab as part of their immuno-suppression protocol following heart transplantation. Literature suggests that the time to first rejection episode can be avoided or delayed by using induction therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-11 |
Why NCT00486057 stopped before completion
NCT00486057 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00486057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00486057 about?
NCT00486057 is a clinical study titled "Daclizumab Experience in Pediatric Heart Transplant". The purpose of this study is to examine the outcomes of those who have received Daclizumab as part of their immuno-suppression protocol following heart transplantation. Literature suggests that the time to first rejection episode can be avoided or delayed by using induction therapy.
What is the current status of trial NCT00486057?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2004-08. Estimated completion is 2007-11.
Who is sponsoring clinical trial NCT00486057?
This trial is sponsored by Children's Healthcare of Atlanta, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia